Namida Lab and CARTI Partner to Study Proteins in Cancer Patients’ Tears
Study will identify whether cancer can be identified through tears
FAYETTEVILLE, AR – Namida Lab,® Inc., a Fayetteville, Arkansas-based biotech company with a mission to develop novel cancer diagnostics based on proteins from tears, has partnered with CARTI, Arkansas’ leading cancer care provider, on a new research study. The study, which will begin in January 2022 and continue for 10 months, will collect tear samples from patients who have been diagnosed with multiple cancers but who have not yet begun treatment. The study is fully funded by Namida Lab, and participants will incur no cost.
“CARTI is honored to participate in this revolutionary trial,” said Sam Makhoul, M.D., medical director of clinical research at CARTI. “Our patients’ tears will provide helpful data that may positively impact the way we can diagnose cancers for years to come. We are proud to partner with Namida Lab as they continue their research and development into cancer screening through tear proteins and cancer biomarkers.”
With 18 treatment locations in 15 communities across the state, CARTI will enroll cancer patients diagnosed with multiple cancers. To participate in this study, individuals must have been diagnosed with breast, ovarian, prostate, melanoma, pancreatic, or colon cancer but not yet have begun treatment.
“We greatly value the opportunity to establish clinical partnerships right here in Arkansas. We know patients are being asked to participate in research at a very stressful time and we appreciate their willingness to help us move our work forward.” says Namida Lab R&D scientist Prashanth Ravishankar.
If you are interested in enrolling in this or other studies at Namida Lab, please visit https://namidalab.com/clinical-trials to learn more.
About Namida Lab
Namida Lab Inc. is an Arkansas-based biotech company specializing in biomarker-based testing to improve diagnostic testing and patient outcomes. Namida’s first product, Melody® is an accurate, inexpensive, and non-invasive test for breast cancer screening available by prescription only. Auria™, a direct-to-consumer short-term breast cancer risk assessment test, will be released in 2022. To learn more please visit www.auria.care
Namida was founded in 2019 and has assembled a talented team with experience across diagnostic, medical information, and scientific automation fields to develop a diagnostic platform leveraging the untapped power of tears. Namida operates a high complexity CLIA (Clinical Laboratory Improvement Amendments) certified lab. Its Research & Development Lab works in tandem with the CLIA Lab to develop medical screening and diagnostic tools.
About CARTI
CARTI is a non-profit, multidisciplinary cancer care provider offering medical and surgical oncology, diagnostic radiology, and radiation oncology. With 18 treatment locations in 15 communities across the state, CARTI's mission is to provide convenient access for cancer patients.
Medical oncology is offered in Little Rock, North Little Rock, Bryant, Clarksville, Clinton, Conway, Crossett, El Dorado, Heber Springs, Magnolia, Pine Bluff, Russellville and Stuttgart. Radiation therapy is offered in Little Rock, North Little Rock, Conway, Mountain Home and Searcy. Mammography screenings are provided at The Breast Center at CARTI, with locations at the CARTI Cancer Centers in Little Rock, North Little Rock and Russellville.
For more information, visit CARTI.com.
